Atherid Therapeutics was founded in 2025 by Perkins researchers associate professor Juliana Hamzah and professor Shirley Jansen. Atherid is developing a drug to deal with Atherosclerosis, which is caused by cholesterol and other lipids building up on the walls of arteries. It has received an initial $750,000 in Medical Research Future Fund through the Targeted Translation Research Accelerator’s Drugs and Devices program delivered by MTP Connect.
